share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

SEC announcement ·  May 31 06:43
Summary by Futu AI
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on May 28, 2024. The transaction was carried out in the open market at a price of $9.1677 per share, resulting in a total sale value of approximately $104,942.66. Following the sale, Borgeson's direct holdings in the company amount to 7,186,913 shares of Common Stock.
Blake Borgeson, a reporting person associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of Class A Common Stock on May 28, 2024. The transaction was carried out in the open market at a price of $9.1677 per share, resulting in a total sale value of approximately $104,942.66. Following the sale, Borgeson's direct holdings in the company amount to 7,186,913 shares of Common Stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.